Alnylam defends against Tekmira complaint.

Alnylam defends against Tekmira complaint, files counterclaim and answer Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics business, has filed a remedy and counterclaim to a complaint filed by Tekmira Pharmaceuticals Corporation in the Business Litigation Session of the Massachusetts Superior Court. Our focus continues to be on the advancement of RNAi therapeutics to sufferers and execution on our clinical programs. .Cedarburg's attractive development pipeline contains multiple late stage products and is expected to be a significant contributor for future development. On a stand-by itself basis, Cedarburg's forecasted full year 2014 revenue is approximately $19 million, with adjusted EBITDA between $5.5 million and $5.7 million, implying a purchase price multiple of around 2 times 2014 revenue and approximately 7 times 2014 modified EBITDA at the midpoint of the number. Altered EBITDA excludes any offer related costs or buy accounting impacts. The purchase is expected to close in early April 2014. Based on the anticipated timing of the close, the acquisition is definitely expected to add between $13 and $14 million to AMRI's income in 2014. AMRI anticipates full year run-rate synergies of around $1.5 million of EBITDA within 12 months of closing and the acquisition is likely to be accretive to AMRI's 2014 adjusted diluted EPS in the number of $0.06 to $0.07 per share.